MSG-15: Super-bioavailability itraconazole versus conventional itraconazole in the treatment of endemic mycoses-A multicenter, open-label, randomized comparative trial

Authors

Andrej Spec, Washington University School of Medicine in St. Louis
et al.

Journal

Open Forum Infectious Diseases

Publication Date

3-1-2024

Volume

11

Issue

3

First Page

ofae010

Document Type

Open Access Publication

DOI

10.1093/ofid/ofae010

Rights and Permissions

Andrej Spec, George R Thompson, Marisa H Miceli, Justin Hayes, Laurie Proia, David McKinsey, Ana Belen Arauz, Kathleen Mullane, Jo-Ann Young, Gerald McGwin, Rachel McMullen, Tyler Plumley, Mary K Moore, Lee Ann McDowell, Carolynn Jones, Peter G Pappas, MSG-15: Super-Bioavailability Itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses—A Multicenter, Open-Label, Randomized Comparative Trial, Open Forum Infectious Diseases, Volume 11, Issue 3, March 2024, ofae010, https://doi.org/10.1093/ofid/ofae010. https://academic.oup.com/ofid/article/11/3/ofae010/7590982?login=true. © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Spec, Andrej and et al., "MSG-15: Super-bioavailability itraconazole versus conventional itraconazole in the treatment of endemic mycoses-A multicenter, open-label, randomized comparative trial." Open Forum Infectious Diseases. 11, 3. ofae010 (2024).
https://digitalcommons.wustl.edu/oa_4/3394

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.